Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

NCT05979415 is registered in ClinicalTrials.gov with Alexza Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05979415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Lead sponsor
Alexza Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 27, 2023
Completion date
February 28, 2024
Enrollment
8 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease